News

August 23, 2023

Businesswire

Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer

Alterome Therapeutics, Inc., a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.

January 5, 2023

Businesswire

Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts.

November 2, 2022

Businesswire

Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies

$35 million extension round led by new investor Colt Ventures and co-led by existing investor OrbiMed with participation from all existing investors

November 2, 2022

Endpoints

Mysterious OrbiMed-backed biotech nears $100M in funding, hints at plans to go after ‘undruggable 3.0’

While the biotech put out a press release for its $64 million Series A, led by OrbiMed, it launched without a website and didn’t elaborate on its science beyond “alteration-specific targeted therapies for the treatment of cancer.”

January 20, 2022

Endpoints

OrbiMed takes point on a new biotech launch, but almost everything remains secret for now

If you missed the news of a new company launch backed by blue-chip investor OrbiMed early Wednesday morning, that was by design. Alterome Therapeutics quietly emerged from stealth with $64 million in its Series A…

January 19, 2022

Businesswire

Alterome Therapeutics Launches With $64M Series A Financing

Alterome Therapeutics, Inc., a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer, announced the closing of a $64M Series A financing…